SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

Food and Healthcare Press Releases Friday August 9, 2019 08:35
RANCHO SANTA MARGARITA, California--9 Aug--PRNewswire/InfoQuest
Food and Drink manufacturers' answer to Singapore's proposed "Sugar Tax"
SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives.
SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with a clean, sugar-like taste and now enables food and beverage manufacturers to reduce sugar, without sacrificing taste.

This approval comes at a time when Singapore is considering a "sugar tax" hoping to change the behaviors of consumers and manufacturers on reducing sugar-based products. Earlier this year, Singapore's Ministry of Health (MOH) proposed multiple measures potentially impacting the food and beverage sectors including banning the sale of higher sugar drinks and imposing a tax on sugar-based drinks.

SweeGen's unique production starts with the stevia leaf and uses a patented bioconversion process to achieve high purity, clean-tasting Reb M. This process enabled SweeGen to obtain the Non-GMO Project verification for Reb M, which was commercialized in 2017 and has been approved in many regions around the world.

"We are excited to introduce our non-GMO Reb M stevia leaf sweetener to food and beverage manufacturers in Singapore," said Lewis Tessarolo, senior director of business development Asia Pacific, SweeGen. "Consumer demand for zero and reduced-sugar products is on the rise globally, and our non-GMO Reb M provides a solution to manufacturers."

Reb M, together with Reb D and e+ is part of SweeGen's non-GMO stevia sweetener portfolio. Consumer demand for zero and reduced-sugar products is on the rise globally, and nature-based stevia sweeteners provide a great tasting alternative to sugar and artificial sweeteners.

About SweeGen

SweeGen, Inc. is dedicated to the development, production and distribution of non- caloric sweeteners for the food, flavor and beverage industries. SweeGen's robust product pipeline, intellectual property portfolio, and dedicated manufacturing capacity and R&D provide the foundation for innovation and delivery of high-quality sweeteners. For more information please contact info@sweegen.com and visit SweeGen's website, www.sweegen.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release contains forward-looking statements, including, among other statements, statements regarding the future prospects for Reb M stevia leaf sweetener. These statements are based on current expectations, but are subject to certain risks and uncertainties, many of which are difficult to predict and are beyond the control of SweeGen, Inc.

Relevant risks and uncertainties include those referenced in the historic filings of SweeGen, Inc. with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from those expressed in or implied by the forward-looking statements, and therefore should be carefully considered. SweeGen, Inc. assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.

Logo - https://mma.prnewswire.com/media/469549/Sweegen_Final_OT_Logo.pdf

Latest Press Release

New Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care

BAVENCIO(R) (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX(R) (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930; 5373; 5455, M6620 (ATR inhibitor): 1547, Combinations: 4062; 4934. - New subgroup analyses for first-line...

CHMP Adopts Positive Opinion for BAVENCIO(R) (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma

- Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Merck and...

Accor Pattaya Blood Donation #3/2019

On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m....

Tresiba(R) Showed an Overall Lower Risk of Hypoglycaemia and Significantly Lower HbA1c When Compared to Insulin Glargine U300 in People With Type 2 Diabetes

According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in...

BookDoc, partners it#s way to being Southeast Asia#s Next Generation Healthcare Ecosystem is looking to raise Series A from Strategic partners

This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate...

Related Topics